Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Company plans to initiate Phase II trial with a leading academic institution. These advanced analytics provide a human-centric, data-driven approach to phenotypic discovery for clients.”. Investor Contact: Robert Schatz.

Pharmaceutical 81

Pharmaceutical Data Clinical Trials Research and Development 81

The Cannigma

MARCH 25, 2021

It is also crucial so that the correct data is collected in order to inform further research and clinical trials that are necessary for cannabis medicines to reach the UK National Health Service. The idea behind the MDT series is to place the unfamiliar cannabis medicines into a familiar case discussion format.

Patients 145

Patients Clinical Trials Medicine Events 145

Cannabis Law Report

AUGUST 10, 2021

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. These statements relate to future events or future performance. from 2020 to 2030 and generate revenue of $151.7 billion in 2030.

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

AUGUST 17, 2021

Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. The immediate next steps are to submit data for ethics committee review and approval whereupon acceptance, further details will be provided. “A

Clinical Trials 40

Clinical Trials Research and Development Pharmaceutical Events 40

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. Guy Goodwin appointed Chief Medical Officer and Danielle Schlosser appointed Senior Vice-President, Clinical Innovation. On track to report top-line data by end of 2021.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. Chief Scientific Officer. MyMD Pharmaceuticals, Inc.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 40

Epilepsy Pharmaceutical Data Clinical Trials 40

Veriheal

MAY 3, 2022

The study was conducted by more than 10 researchers, with leads Dr. Jodi Gilman and Dr. Kevin Potter taking responsibility for the integrity and accuracy of the data. Clinical Trial Sample Size. Does the Data Justify the Conclusions? Investigating the Impact of MMJ Cards.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Veriheal

JULY 12, 2021

According to the American Psychiatric Association , PTSD is a “psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as natural disaster, as a serious accident, a terrorist act, war/combat or rape or who have been threatened with death, sexual violence or serious injury”.

Treatment 105

Treatment Sleep Clinical Trials Data 105

Project CBD

MAY 3, 2023

It’s noteworthy that much of this anecdotal data is supported by findings from preclinical research. Dr. Goldstein: We don’t have clinical trials to say, yes this is definitively beneficial or detrimental for children. But we may be on the cusp of having those trials, which would be very exciting.

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Consumers spent roughly $31.3 increase in annual sales. Accessed July 25, 2021.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JULY 28, 2021

The results also provide confidence in the Company’s plan to dedicate resources to advance PD-001 through FDA IND-enabling studies to support Phase 1 and 2 clinical studies. Previously the Company announced that it had secured FDA Orphan Drug Designation for cepharanthine in the treatment of esophageal cancer. ” Next Steps.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

JUNE 7, 2021

FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. Supera-CBD is being developed to address the rapidly growing CBD market, that includes FDA approved drugs and CBD products not currently regulated as a drug. For more information, visit www.mymd.com. 646-536-7331.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

Cannabis Law Report

SEPTEMBER 22, 2021

Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. We look forward to providing continuing updates as we advance this drug candidate in the clinic.”.

Pharmaceutical 40

Pharmaceutical Data CBD Clinical Trials 40

The Joint Blog

APRIL 21, 2020

This is according to a study published in the Journal of Clinical Medicine Research and epublished by the U.S. For the study researchers with the Nordic Cannabis Research Institute in Denmark reviewed 25 clinical trials assessing the safety and efficacy of CBD in various populations. National Institute of Health.

Clinical Trials 52

Clinical Trials CBD Safety Patients 52

Cannabis Law Report

NOVEMBER 12, 2021

In the event that the Maximum LTV is exceeded, Brown Shipley can make a call on the Guarantors requiring them to place cash with Brown Shipley for the aggregate amount of the excess exposure over the Maximum LTV. OCT is conducting pre-clinical testing and development with pre-clinical trials scheduled for 2022.

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Cannabis Law Report

AUGUST 3, 2021

FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration (U.S. For Applied DNA: Investor contact: Sanjay M.

Clinical Trials 81

Clinical Trials Therapy Collective Research and Development 81

Cannabis Law Report

SEPTEMBER 2, 2021

FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration (U.S. For Applied DNA: Investor contact: Sanjay M.

Clinical Trials 76

Clinical Trials Research and Development Therapy Collective 76

Cannabis Law Report

DECEMBER 7, 2021

While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events. In conclusion, cannabidiol is associated with clinical improvement in Dravet syndrome. 1.69, 95% CI [1.20–2.36]) 1), 95%CI [??1.39–(??0.60)])

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

NOVEMBER 12, 2021

Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. On track to commence Phase 2 proof-of-concept clinical trial with ANEB-001 for the treatment of acute cannabinoid intoxication by year-end. Condensed Balance Sheet Data. . . The founding co-chairs are Andrew Monte, M.D.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

JANUARY 13, 2020

Continue to explore CBDV in autism through a combination of open-label and investigator-led placebo controlled clinical trials with data from one or more of these programs in 2020. Execute NHIE clinical program utilizing an intravenous formulation of cannabidiol. Forward-looking statements. 917 280 2424 / 401 500 6570.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

Cannabis Law Report

JUNE 7, 2021

1.526 were reduced as expected and consistent with other CDC-reported data on vaccine-induced antibody neutralization against these variants 1. Department of Agriculture (USDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final or conditional approval from the U.S.

Clinical Trials 49

Clinical Trials Research and Development Therapy Supply Chain 49

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Topical 40

Cannabis Law Report

JUNE 2, 2021

FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration (U.S. For Applied DNA: Investor contact: Sanjay M.

Clinical Trials 63

Clinical Trials Therapy Collective Research and Development 63

Cannabis Law Report

JANUARY 3, 2022

“Additionally, we are pleased with the guidance provided by the FDA regarding ANEB-001’s clinical and regulatory path in the U.S. We were able to rapidly incorporate the FDA’s feedback into the design of the current Phase 2 trial to make the data generated in Europe as relevant as possible for a potential future NDA submission.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

Cannabis Law Report

JANUARY 6, 2022

Following his successful tenure at Amazon, Leslie made the leap to the burgeoning cannabis industry where he served as CEO of one of the world’s most authoritative digital cannabis data sources, Leafly. The synergies could not be better aligned,” Leslie said. “I Forward-looking statements are only predictions.

Research and Development 52

Research and Development Events Clinical Trials Business 52

Cannabis Law Report

JANUARY 12, 2022

As Oregon prepares to roll out the nation’s first legal psilocybin-assisted services program, there is a recognized need for the community to track adverse events and measure efficacy. Through the right mix of regulation, technology, and data, both are equally achievable,” says NPA CEO Britt Rollins.

Research and Development 52

Research and Development Therapy Clinical Trials Safety 52

Cannabis Law Report

JULY 4, 2019

The programme aims to investigate mechanisms of action of cannabis-based medicinal products related to several clinical applications including pain and cancer, as well as characterise cannabis-based medicinal products in disease models with particular focus of chronic pain, spasticity and cancer.

Cannabinoids 40

Cannabinoids Clinical Trials Chronic Pain Medicine 40

Cannabis Law Report

FEBRUARY 2, 2022

– Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA). Dr. Manalo-Morgan has spent the last 5 years researching cannabis and has specialized in the formulation of cannabinoid products for clinical trials.

Cannabinoids 40

Cannabinoids Clinical Trials Events Cultivation 40

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 40

Clinical Trials Research and Development Therapy Supply Chain 40

Cannabis Law Report

NOVEMBER 26, 2021

With the anticipated launch of Pfizer’s oral COVID-19 antiviral drug candidate, Can-Fite has made a strategic decision to end its COVID-19 program and to focus its resources on its other clinical programs, all in advanced clinical trials. dollars in thousands (except for share and per share data). . . Financial Results.

Clinical Trials 40

Clinical Trials Research and Development Treatment Data 40

Cannabis Law Report

JANUARY 6, 2022

He serves as the primary spokesperson and point of contact with the analyst and investment community and is also responsible for the timely dissemination of information and data to these important stakeholders. Anderson will be responsible for Anebulo’s global investor relations and public relations programs.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52